The Role of Spreader Grafts in Reduction Rhinoseptoplasty: a Randomized Clinical Trial With Quality of Life Assessment
Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · Jul 31, 2020
Trial Information
Current as of July 01, 2025
Unknown status
Keywords
ClinConnect Summary
Reduction rhinoplasty and rhinoseptoplasty are among the most accomplished aesthetic procedures in Plastic Surgery and Otorhinolaryngology. Nasal obstruction is one of the majors concerns in this procedures, because it affects quality of life and surgical outcomes. Nasal surgeons have paid much attention to nasal valve area to prevent nasal obstruction and some assert reconstruction of the middle vault after dorsal reduction with grafts. The gold standard for middle vault reconstruction after dorsal reduction has been the spreader graft, first advocated by Sheen. Studies in surgical techniq...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients eligible for reduction rhinoseptoplasty who agreed to participate in the study and who did not meet the exclusion criteria
- Exclusion Criteria:
- • Absence of nasal obstruction;
- • Previous nasosinusal surgery;
- • Symmetrical or asymmetric insufficiency of the middle third that would justify the placement of middle third grafts for the treatment of these problems;
- • Presence of nasal valve insufficiency as the only cause of nasal obstruction;
- • Cranio-facial anomalies;
- • Presence of nasosinusal tumors;
- • Active acute rhinosinusitis;
- • Patients undergoing treatment of other entities concomitant to rhinoseptoplasty such as: sinus inflammatory surgery, adenoid hypertrophy removal, septal perforation correction, otoplasty or blepharoplasty.
About Hospital De Clinicas De Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA) is a leading academic medical center in Brazil, renowned for its commitment to advancing healthcare through innovative clinical research. As a sponsor of clinical trials, HCPA leverages its extensive expertise in various medical disciplines to conduct rigorous studies aimed at improving patient outcomes and contributing to the global medical community. With a multidisciplinary team of skilled professionals and state-of-the-art facilities, HCPA fosters a collaborative environment that prioritizes ethical standards, patient safety, and scientific integrity in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rs, Brazil
Patients applied
Trial Officials
Michelle Lavinsky-Wolff, PhD
Study Director
Federal University of Health Science of Porto Alegre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials